Form 4: Kymera Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares
SEC Form 4 Filing
Jared Gollob, Chief Medical Officer of Kymera Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 15 and 16, 2024, Jared Gollob, the Chief Medical Officer of Kymera Therapeutics, executed stock options to purchase shares of common stock at a price of $2.08 per share.
- He then sold portions of these shares on the same days at weighted average prices ranging from $45.1489 to $46.0965.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 22, 2023.
- Following these transactions, Gollob directly owns 95,470 shares of Kymera Therapeutics common stock and holds options to buy 22,883 more shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity under a pre-existing plan.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not appear to have any impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2019-02-07 | Vesting commencement date for stock options. |
| 2023-03-22 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-07-15 | Date of first reported transaction (option exercise and share sale). |
| 2024-07-16 | Date of second reported transaction (option exercise and share sale). |
| 2029-05-22 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.